Trial · NCT03509207
Vorinostat (SAHA) in Uterine Sarcoma
NCT03509207, Phase 2, Terminated, Medical University of Graz; results first posted 2020-07-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vorinostat (SAHA) in Uterine Sarcoma. Trials, record NCT03509207. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03509207
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vorinostat (SAHA) in Uterine Sarcoma
- NCT number
- NCT03509207
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Medical University of Graz
- Conditions
- Leiomyosarcoma, Endometrial Stromal Tumors, Carcinosarcomas Uterine
- Interventions
- Vorinostat Oral Capsule
- First posted
- 2018-04-26
- Last updated
- 2020-08-04
- Results first posted
- 2020-07-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | 9 months | Change from Baseline Tumor Size to last available observation with respect to progress as defined by RECIST 1.1 (CT-Scan every 12 weeks up to 9 months) |
| Secondary | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | 9 months | This endpoint is evaluated by the amount of clinical adverse experiences. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) | 9 months | Only one Patient reached the first end Point. Statistical Evaluation was therefore not possible. For this reason no data are reported in the data table. | ||
| SECONDARY | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | 9 months | Only one Patient reached the first end Point. Statistical Evaluation was therefore not possible.~For this reason no data are reported in the data table. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Vorinostat, Zolinza Oral Capsules | 3 | |
| Overall Study | COMPLETED | Vorinostat, Zolinza Oral Capsules | 1 | |
| Overall Study | NOT COMPLETED | Vorinostat, Zolinza Oral Capsules | 2 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death of uterine carcinoma | Reproductive system and breast disorders | Vorinostat, Zolinza Oral Capsules | 2 | 3 | 2 |
| serious | pleural effusion | Respiratory, thoracic and mediastinal disorders | Vorinostat, Zolinza Oral Capsules | 2 | 3 | 2 |
| serious | abscess of the vaginal vault | Reproductive system and breast disorders | Vorinostat, Zolinza Oral Capsules | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vorinostat, Zolinza Oral Capsules | 2 | 3 |
| Total, other adverse events | Vorinostat, Zolinza Oral Capsules | 0 | 3 |
| Total, serious adverse events | Vorinostat, Zolinza Oral Capsules | 2 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03509207
GET https://conductscience.org/api/trials/v1/NCT03509207/registered